TRAIP antibodies are designed to target the 53.3 kDa TRAF-interacting protein, a 469-amino-acid protein localized in the nucleus and cytoplasm . Key features include:
Synonyms: SCKL9, TRIP, RNF206, E3 ubiquitin-protein ligase TRAIP
Protein Family: TRAIP/RNF206
Post-Translational Modifications: Ubiquitination, sumoylation
Orthologs: Conserved in mouse, rat, bovine, zebrafish, and primates
TRAIP antibodies are widely used to investigate:
DNA Repair Mechanisms: TRAIP regulates DNA interstrand cross-link (ICL) repair by promoting CMG helicase convergence, critical for Fanconi anemia pathway activation .
Replication-Transcription Conflicts: Depletion of TRAIP causes DNA damage at transcription start sites during S-phase, leading to G2 arrest and senescence .
Genome Integrity: TRAIP binds PCNA and facilitates RPA-coated single-stranded DNA formation during replication stress, enhancing ATR-dependent checkpoint signaling .
TRAIP-deficient cells exhibit chromosomal instability and reduced survival under replication stress .
In mitosis, TRAIP ubiquitylates CMG helicases to ensure replisome integrity .
Rapid TRAIP degradation triggers G2 arrest and senescence, emphasizing its S-phase role in resolving replication-transcription collisions .
TRAIP loss delays mitotic progression, independently contributing to DNA damage in subsequent cell cycles .
Cancer: TRAIP promotes proliferation in prostate cancer via TRAF2-PI3K-AKT pathway activation and enhances osteosarcoma invasion through IGFBP3/AKT signaling .
Microcephalic Dwarfism: TRAIP mutations impair ICL repair, linking its dysfunction to developmental disorders .